Mode
Text Size
Log in / Sign up
Phase 3 Completed N=460 Randomized Double-blind Treatment

A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease

Source: ClinicalTrials.gov NCT01664949 ↗
Enrolled (actual)
460
Serious AEs
2.0%
Results posted
Jun 2015
Primary outcomePrimary: Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Day 90 — 41.77; 40.92; -16.88; -15.97 score on a scale

Summary

This study will evaluate the safety and efficacy of a carboxymethylcellulose based eye drop formulation compared with carboxymethylcellulose based preservative-free lubricant eye drops (OPTIVE™) in subjects with dry eye disease.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Day 90
41.77; 40.92; -16.88; -15.97
SECONDARY
Change From Baseline in Tear Break-up Time (TBUT)
4.50; 4.44; 2.69; 2.24
SECONDARY
Change From Baseline in Corneal Staining
1.5; 1.6; -0.7; -0.9
SECONDARY
Change From Baseline in Conjunctival Staining
2.8; 3.0; -1.3; -1.4
SECONDARY
Change From Baseline in the Schirmer Test
9.29; 8.10; 1.38; 1.53

Eligibility Criteria

Inclusion Criteria

  • Have used artificial tears for dry eye

Exclusion Criteria

  • Start date of over the counter, herbal, prescription or nutritional supplements that may affect dry eye or vision within 3 months prior to study start or an anticipated change in dosage during the study
  • History of eye surgery or trauma in the 6 months prior to study start
  • Current use or use within 2 weeks of study start, of topical eye medications.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01664949). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search